01 January 2001
Primary hepatic carcinoid tumor: case report and review of 53 cases.
Masataka Iwao, Makoto Nakamuta, Munechika Enjoji, Hiroaki Kubo, Takayoshi Fukutomi, Yuichi Tanabe, Hidehiro Nishi, Ken-ichi Taguchi, Kazuhiro Kotoh, Hajime NawataMed Sci Monit 2001; 7(4): CS746-750 :: ID: 421075
Abstract
BACKGROUND: Primary hepatic carcinoid tumor (PHCT) is a extremely rare.The authors describe a patient with PHCT and review previously published cases of the disease.
CASE REPORT:A 75-year-old man, presenting with weight loss and pain in the right upper abdomen, had multiple massesin both lobes of the liver. He was diagnosed as PHCT by radiological examination, laboratory findingswith high levels of 5-hydroxyindoleacetic acid (5-HIAA) in the serum and urine, and histological findingsincluding positive staining of tumor cells for Grimelius and chromogranin A. The patient received totallytranscatheter arterial chemoembolization (TACE) five times over 27 months; this treatment provided excellentpalliation and caused a decrease in urinary 5-HIAA levels. Fifty-three cases of PHCT have been reportedin the English-language literature.
RESULTS: Analysis of these published cases revealed that PHCT occursin the middle age (mean age = 48.2 years) and is more frequent in females (males/females = 20/33 cases).Of the symptomatic patients, the major findings is abdominal pain, fullness, and/or a palpable mass (56%of symptomatic patients). In contrast, only 2 cases out of 53 presented with symptoms of typical carcinoidsyndrome. In most cases, PHCT was detected as a hypervascular lesion by radiological examination. Byhistological analysis, 80% and 84% of the cases were positive for Grimelius silver stain and immunohistochemicallypositive for chromogranin A, respectively. Surgical resection is the treatment primarily recommendedwith an 18% of recurrence rate and a 74% of a survival rate after 5 years. For unresectable and recurrentcases, TACE may be recommended.
Keywords: Primary hepatic carcinoid tumor
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952